Get started
Author

Duncan Murray

Observed names: D. Murray, Duncan J Murray, Duncan J. Murray, Duncan James Murray, Murray, Duncan James
Observed institutions: University Hospitals Birmingham NHS Foundation Trust, University Hospital Coventry, University Hospitals Coventry and Warwickshire NHS Trust, Heartlands Hospital, Coventry (United Kingdom), University of Birmingham
ORCID: 0000-0003-4664-3725
Observed ORCID: 0000-0003-4664-3725
OpenAlex ID: A5045319564
Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS
2024 · Jad Othman, Ho Pui Jeff Lam, et al. · Blood Neoplasia · 55
Progression of mycosis fungoides occurs through divergence of tumor immunophenotype by differential expression of HLA-DR
2019 · Duncan Murray, Jack Luke McMurray, et al. · Blood Advances · 35
PDF
The number of CD56dim NK cells in the graft has a major impact on risk of disease relapse following allo-HSCT
2017 · Luke Maggs, Francesca Kinsella, et al. · Blood Advances · 29
PDF
Outcomes with single-agent gilteritinib for relapsed or refractory FLT3 -mutant AML after contemporary induction therapy
2024 · Jad Othman, Angela Hwang, et al. · Blood Advances · 16
A Hybrid Architecture (CO-CONNECT) to Facilitate Rapid Discovery and Access to Data Across the United Kingdom in Response to the COVID-19 Pandemic: Development Study
2022 · Emily Jefferson, Christian Cole, et al. · Journal of Medical Internet Research · 15
PDF
Very early lineage-specific chimerism after reduced intensity stem cell transplantation is highly predictive of clinical outcome for patients with myeloid disease
2019 · Francesca A.M. Kinsella, Charlotte F. Inman, et al. · Leukemia Research · 15
Phase II trial of atezolizumab (Anti-PD-L1) in the treatment of relapsed/refractory IIB/IVB mycosis fungoides/Sézary syndrome patients after previous systemic treatment. EORTC-1652-CLTG “PARCT”
2025 · Rudolf Stadler, Gabriele Roccuzzo, et al. · European Journal of Cancer · 12
PDF
A 3-week pause versus continued Bruton tyrosine kinase inhibitor use during COVID-19 vaccination in individuals with chronic lymphocytic leukaemia (IMPROVE trial): a randomised, open-label, superiority trial
2025 · Jonathan A Cook, Piers E M Patten, et al. · The Lancet Haematology · 9
Machine learning of COVID-19 clinical data identifies population structures with therapeutic potential
2022 · David Greenwood, Thomas Taverner, et al. · iScience · 5
PDF
Gilteritinib for Relapsed Acute Myeloid Leukaemia with FLT3 Mutation during the COVID-19 Pandemic: Real World Experience from the UK National Health Service
2021 · Jad Othman, Usman Afzal, et al. · Blood · 5
PDF
The Impact of Pausing Bruton Tyrosine Kinase Inhibitor Therapy and Responsiveness of Vaccination in Blood Cancer Patients: Primary Outcome Result for the Randomised Improve Trial
2023 · Piers Patten, Jonathan Cook, et al. · Blood · 3
A HaemSTAR-led, UK-wide 'flash-mob’ audit of intravenous immunoglobulin use in immune thrombocytopenia
2019 · Phillip Nicolson, Rita Perry, et al. · Clinical Medicine · 3
PDF
COVID‐19 in haematology patients: a multicentre West Midlands clinical outcomes analysis on behalf of the West Midlands Research Consortium
2020 · Hana Morrissey, Patrick Ball, et al. · British Journal of Haematology · 2
Allogeneic haematopoietic stem cell transplantation in advanced cutaneous T-cell lymphomas offers curative potential
2025 · Agni Hatzakis, Bernard D. Maybury, et al. · Bone Marrow Transplantation · 1
Defective T‐cell response to COVID ‐19 vaccination in acute myeloid leukaemia and myelodysplastic syndromes
2023 · Justin Loke, Vinit Upasani, et al. · British Journal of Haematology · 1
PDF
Acute Myeloid Leukemia: Low Peripheral Blast Count May Predict Better Outcome with Best Supportive Care Than with Intensive Chemotherapy in Older Patients
2012 · Duncan J Murray, Jhansi Muddana, et al. · Blood · 1
LY12 Primary cutaneous large cell anaplastic lymphoma and lymphomatoid papulosis: clinical characteristics, treatment patterns and outcomes from a UK supraregional skin lymphoma centre
2026 · Ebun Oluwole, Abraham Bashir, et al. · British Journal of Dermatology
Observing the cancer microenvironment in mycosis fungoides following immune checkpoint blockade
2025 · Duncan Murray, Samantha Drennan, et al. · European Journal of Cancer
Evaluating Interferon therapy for CTCL: Real-world evidence from a UK centre
2025 · Amirtha Rajasekaran, Abraham E. Bashir, et al. · European Journal of Cancer
Real-World use of brentuximab vedotin in CD30+ Cutaneous lymphomas: a retrospective analysis from a UK tertiary centre
2025 · Vidette Wong, Abraham E. Bashir, et al. · European Journal of Cancer
Real-world experience with Chlormethine gel for Mycosis Fungoides treatment: results from a UK centre
2025 · Harsharan Kaur, Abraham E. Bashir, et al. · European Journal of Cancer
PA26 Folliculotropic mycosis fungoides with large cell transformation in an adolescent patient
2025 · Natalie King Stokes, Sridhar Chaganti, et al. · British Journal of Dermatology
PDF
A-289 Allogeneic stem cell transplantation in advanced cutaneous T cell lymphoma offers the potential for cure
2024 · A. Hatzakis, B. Rooke, et al. · European Journal of Cancer
A-202 Validation Of Next Generation Sequencing Using EuroClonality-NDC Panel In Primary Cutaneous Lymphomas and comparison with Traditional PCR Techniques
2024 · A. Hatzakis, M. Pugh, et al. · European Journal of Cancer
Eosinophilia in Rheumatology: A Management Challenge
2024 · Michael Alsharkawy, Duncan Murray, et al. · EMJ Rheumatology
Works count: 38
Citation count: 207
H-index: 8
I10-index: 7
Year
Topic
Type